

REMARKS

Claims 47-50 are pending. Claims 1-46 and 51-75 have been cancelled without prejudice. Applicants reserve the right to prosecute subject matter withdrawn from consideration by cancellation in one or more continuation, continuation-in-part, or divisional applications.

THE RESTRICTION REQUIREMENT

In the Official Action, restriction under 35 U.S.C. §121 is required to one of the following groups of inventions:

I. Claims 1-24 drawn to a method of identifying a ligand capable of binding to at least one determinant of a biologically active site on a target, which determinant participates in conferring biological activity of said target;

II. Claims 25-46 drawn to a method of identifying ligands capable of binding at least two determinants which together are required for biological activity of a pharmaceutical target;

III. Claims 47-50 drawn to a reporter;

IV. Claims 51-54 drawn to a method wherein two peptides are attached to the rVab component to form rVap-Pep²;

V. Claims 55-59 drawn to a method of identifying a ligand capable of binding to at least one determinant of a biologically active site on a target, which target requires activation of at least two determinants to express biological activity of said target;

VI. Claims 60-74 drawn to a recombinant rVab antibody library comprising rVab members possessing at least one VL and VH region derived from a parental variable region with at least one CDR which is diversified to form different rVab members by deleting, inserting, or substituting at least one amino acid within at least one CDR; and

VII. Claim 75 drawn to a method of providing a model for a ligand capable of binding to a determinant of an active site of a pharmaceutical target.

In order to be fully responsive, Applicants elect the invention of Group III, claims 47-50, with traverse, to prosecute in the present application without prejudice to prosecution of the subject matter of the non-elected Groups in subsequent applications.

CONCLUSION


It is believed that the elected claims are in condition for allowance. Early and favorable action by the Examiner is earnestly requested.

AUTHORIZATION

No additional fee is believed due other than the extension of time submitted herewith. However, the Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. 13-4500, Order No. 2598-4000US4.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: April 3, 2006



Melissa B. Wenk
Registration No. 53,759

Correspondence Address:

Morgan & Finnegan, L.L.P.
3 World Financial Center
New York, New York 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile

27123

↑CUSTOMER NUMBER↑